The U.S. Food and Drug Administration has greenlit Miplyffa (arimoclomol), an oral drug designed for managing Niemann-Pick disease type C (NPC).

OPUVIZ has received a recommendation for approval for adult patients in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Tolebrutinib showed a 31% delay in the onset of confirmed disability progression in a phase 3 study of non-relapsing secondary progressive multiple sclerosis.

Tectonic Therapeutic Shares Positive Safety, Tolerability, and PK/PD Phase 1a Results for Lead Candidate TX45.

Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.

Beacon Therapeutics Shares 36-Month Interim Data from HORIZON Phase I/2 Trial of AGTC-501 for XLRP Patients.

RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.

Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.

4DMT Showcases Strong and Lasting Clinical Outcomes for 4D-150 and Unveils 4FRONT Phase 3 Program Plan at 4D-150 Wet AMD Development Event.

Transcenta Shares Promising Results from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024.

Genentech revealed favorable topline results from the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).

Satellos Bioscience announced that the initial participant has received a dose in a Phase 1 clinical trial of SAT-3247.